Archives     Advertise     Editorial Calendar     Subscribe     Contact Us    


Alexander Leads Bipartisan Support for Accelerated FDA Reviews


 

On Aug. 2, the U.S. Senate passed bipartisan legislation led by health committee Chairman Lamar Alexander (R-Tenn.) and Ranking Member Patty Murray (D-Wash.) intended to speed approval of safe drugs and medical devices.

Alexander said: "The Senate has sent to the president's desk legislation that will speed cures and treatments into patients' medicine cabinets. The first step was last year's passage of 21st Century Cures to spur medical research, and this is the next step -- ensuring patients see the benefits of those research advancements."

The legislation includes four different user fee agreements that must be reauthorized by Sept. 30. The bill is virtually identical to legislation overwhelmingly approved by the Senate's health committee on May 11. This legislation will reauthorize the authority for the Food and Drug Administration (FDA) to accept user fees - paid by manufacturers of drugs and medical devices - that account for $8 to $9 billion over 5 years and is over a quarter of all FDA funding. The reauthorizations are based on recommendations from industry and FDA after a public process.

Over the last year and a half, the HELP Committee that Alexander chairs has held 15 bipartisan briefings, including some with the House Energy and Commerce Committee, to hear from FDA and industry about the reauthorization. The HELP Committee held two bipartisan hearings, on March 21 and April 4, on the medical device and drug user fees. The committee held a markup on the bill on May 11, when two bipartisan amendments were adopted, and the committee overwhelmingly approved the bill -- voting 21 to 2.

The bill includes provisions from:

  • Sens. Isakson and Bennet to improve the medical device inspection process.
  • Sens. Hassan and Young to improve communication about abuse-deterrent opioid products.
  • Sens. Enzi and Franken to encourage medical device development for children, and make sure FDA has appropriate expertise to review devices for children.
  • Sens Roberts, Donnelly, and Burr to allow more appropriate classification of accessories used with medical devices.
  • Sens Collins, Franken, McCaskill, and Cotton to improve generic drug development and help lower prescription drug costs.
  • Sens. Hatch, Bennet, Burr, and Casey to improve access to clinical trials for all patients.
  • Sens. Bennet, Rubio, Van Hollen, and Gardner to increase the development of new drugs to treat pediatric cancers and other diseases.
 
Share:

Related Articles:


Recent Articles

The 2019 Legislative Agenda

A new governor and many new legislators make 2019 a learning year as the state's top healthcare organizations seek to address a number of old issues and tweak some new solutions unveiled last year.

Read More

Updated Cholesterol Guidelines Take a Personalized Approach

The American Heart Association and American College of Cardiology released updated cholesterol clinical guidelines in November 2018, taking a more nuanced approach to care over a patient's lifetime.

Read More

Sharing Data, Saving Lives

In an increasingly connected medical ecosystem where patient safety, health status improvement, and provider reimbursement are impacted at every point along the continuum, the need to efficiently, securely share data appears to have reached a tipping point.

Read More

New Rules in Heart Disease

A number of guideline changes and updates warrant more education around statin use and blood pressure monitoring, but local cardiologists say the higher standards are a game changer.

Read More

Dr. Ashish Shah: A Heart for Transplant Patients

Dr. Ashish Shah is the driving force behind the growth and innovation at one of the nation's busiest heart transplant programs.

Read More

Heart Monitor

Cardiovascular news of note.

Read More

ECMO Program Thriving at TriStar Centennial

A TriStar Centennial, a team approach is key to hospital's successful ECMO program.

Read More

Alexander Looks for Innovation, Asks Council Fellows for Input

Sen. Lamar Alexander asks stakeholders and future leaders to weigh in on ways to improve health outcomes, lower costs.

Read More

CMS Utilizes Dartboard Approach to Modernizing the Medicare Drug Benefit

Controlling pharmaceutical prices remains a hot topic, judging from the 6,415 comments received in response to the CMS proposed rule: "Modernizing Part D and Medicare Advantage to Lower Drug Prices and Reduce Out-of-Pocket Expenses."

Read More

A Conversation with LHC Director Molly Vice

Every company should have a succession plan. LHC plays a key role in planning for the next generation of leaders for an entire industry.

Read More

Email Print
 
 

 

 


Tags:
FDA, HELP Committee, Lamar Alexander, U.S. Senate
Powered by Bondware
News Publishing Software

The browser you are using is outdated!

You may not be getting all you can out of your browsing experience
and may be open to security risks!

Consider upgrading to the latest version of your browser or choose on below: